Pediatric Graves' disease: management in the post-propylthiouracil Era

Area of Science:

• Pediatric Endocrinology
• Thyroidology
• Internal Medicine

Background:

• Graves' disease (GD) is the most common cause of thyrotoxicosis in pediatric populations.
• Remission rates with initial therapy are modest, necessitating definitive treatment in most children.
• Accurate diagnosis and management are crucial for long-term health outcomes.

Purpose of the Study:

• To outline current management strategies for pediatric Graves' disease.
• To emphasize the risks and benefits of different treatment modalities.
• To highlight the need for specialized care in managing pediatric GD.

Main Methods:

• Review of current literature and clinical guidelines for pediatric Graves' disease management.
• Comparison of efficacy and safety profiles of antithyroid drugs, radioactive iodine, and surgery.
• Discussion of age-specific considerations and potential complications.

Main Results:

• Methimazole (MMI) is the preferred antithyroid drug due to safety concerns with propylthiouracil (PTU).
• Radioactive iodine ((131)I) therapy requires specific dosing ( > 150 uCi/gm thyroid tissue) and should be used cautiously in younger children due to radiation exposure.
• Near-total or total thyroidectomy is recommended for surgical management, necessitating experienced pediatric thyroid surgeons due to higher complication rates.

Conclusions:

• Most pediatric patients with Graves' disease require treatment beyond initial antithyroid drug therapy.
• Treatment decisions should weigh the risks of radioactive iodine and surgery against potential benefits, considering patient age and gland size.
• Management of pediatric Graves' disease is complex and requires a multidisciplinary approach with physicians experienced in the field.